- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sarah Cannon Research Institute | Strategic Alliance Partners
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI joined with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S. Learn more about our research offerings.
Connect with us:
Latest from Sarah Cannon Research Institute
Renal Cell Carcinoma Histology and Risk Stratification
March 17, 2023
Video
Experts on renal cell carcinoma describe the RCC histologies and tools used for risk stratification.
Overview of Renal Cell Carcinoma
March 17, 2023
Video
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, open the discussion with an overview of renal cell carcinoma.
Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion
March 14, 2023
Article
Precision medicine and personalized medicine are 2 concepts that have pushed their way to the forefront of oncology practice.
Unmet Needs and Future Perspectives in the NSCLC Treatment Landscape
February 21, 2023
Video
Looking to the future, a panel of experts offer closing remarks on promising developments and unmet needs in the treatment of NSCLC.
FDA Approval Insights: Zanubrutinib in CLL and SLL
February 16, 2023
Podcast
Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Neoadjuvant Therapy and Other Emerging Therapies in Early Stage NSCLC
February 14, 2023
Video
Experts discuss the role of neoadjuvant therapy and other emerging therapies in the treatment of early-stage NSCLC.
Treatment Approach for Patients With Stage II-IIIA NSCLC
February 14, 2023
Video
Jaspal Singh, MD, MHS, shares insights on treatment strategies for patients with stage II-IIIA NSCLC.
Raising the Bar for KRAS G12C+ Colorectal Cancer Treatment
February 07, 2023
Article
With 2 KRAS G12C inhibitors showing encouraging results in combination with anti-EGFR agents, there is a ray of hope for patients with recurrent colon cancer–a treatment that may offer patients the chance to make it to important milestones.
Patient Profile 2: Former Smoker Diagnosed With NSCLC
February 07, 2023
Video
David H. Harpole Jr, MD, presents a case of a former smoker diagnosed with NSCLC, and David Spigel, MD, offers his initial impressions.
Choosing Appropriate Patients for Surgical Resection in NSCLC
February 07, 2023
Video
An expert panel shares perspectives on how to choose the appropriate patients with non-small cell lung cancer for lung resection.
Dr. Maris on Key Results From the OUTREACH Trial of Liso-cel in DLBCL
February 01, 2023
Video
Michael Maris, MD, discusses key efficacy and safety data from the phase 2 OUTREACH trial in diffuse large B-cell lymphoma.
Therapies Targeting Specific Molecular Alterations in NSCLC
January 31, 2023
Video
A panel of distinguished experts discuss how detection of actionable mutations affect their treatment choices in non-small cell lung cancer.
Adjuvant Therapy in Early Stage NSCLC
January 31, 2023
Video
David Spigel, MD, and David H. Harpole Jr, MD, describe when adjuvant therapy is recommended in early stage NSCLC and discuss data from recent clinical trials of adjuvant therapy.
Dr. Flinn on the FDA Approval of Zanubrutinib in CLL/SLL
January 25, 2023
Video
Ian Flinn, MD, PhD, discusses the significance of the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Novel Biomarker Tests Increase Accuracy of Breast and Lung Cancer Diagnoses
January 23, 2023
Article
Andrew McKenzie, PhD, discusses biomarkers to test for in breast and lung cancers, the value of multicancer early detection, and how biomarker testing can better direct targeted treatment across solid tumors.
FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC
December 15, 2022
Podcast
Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.
Dr Berdeja on the Safety and Efficacy of BMS-986393 in R/R Multiple Myeloma
December 11, 2022
Video
Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.
Targeted Therapies and Expanded NGS Access Improve Decision Making in Lung Cancer
November 03, 2022
Article
Melissa L. Johnson, MD, shares key insights from the meeting, including pertinent findings in KRAS G12C¬–mutated NSCLC from the phase 3 CodeBreak 200 study and positive findings with atezolizumab in platinum-ineligible patients with NSCLC.
Dr. Johnson on the Effect of the IPSOS Trial on Treatment in Platinum-Ineligible NSCLC
November 02, 2022
Video
Melissa L. Johnson, MD, discusses the paradigm-shifting results of the phase 3 IPSOS trial of atezolizumab in patients with metastatic non–small cell lung cancer.
Dr. McKenzie on Navigating the Landscape of Biomarker Testing in NSCLC
October 24, 2022
Video
Andrew McKenzie, PhD, discusses the variety of molecular testing modalities in patients with metastatic non–small cell lung cancer.